RAID: Role of Adrenaline in in the Inflammatory Response in Diabetes
Study Details
Study Description
Brief Summary
The primary aim of the present study is to study the effect of adrenaline administration on inflammatory parameters (e.g. leukocyte phenotype, cytokines, inflammatory proteins). Secondary objectives consist of the effect of adrenaline on atherogenic parameters.
-
All participants will receive intravenous infusion of adrenaline for an hour
-
We will draw blood at 7 time points, not including screening
-
Participants will be asked to return for a total of 4 times
Researchers will compare 2 groups, healthy individuals versus people with diabetes type 1 to see if the inflammatory reaction to adrenaline differs between these two groups.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| N/A |
Detailed Description
Objective: The primary aim of the present study is to study the effect of adrenaline administration on inflammatory parameters (e.g. leukocyte phenotype, cytokines, inflammatory proteins). Secondary objectives consist of the effect of adrenaline on atherogenic parameters.
Potentially eligible adult ( 16 - 75 years) participants will be recruited from the diabetes clinic at the department of internal medicine from the Radboud University Medical Center. Healthy participants will be recruited through social media and other advertisements. Researchers will recruit a total of 30 individuals, i.e. 15 healthy participants and 15 people with type 1 diabetes. Participants with type 1 diabetes will be equipped with a blinded continuous glucose monitoring device (CGM) during the test, which will measure interstitial glucose levels for a total of 10 days.
Intervention: All participants will receive intravenous infusion of adrenaline at a rate of 0.04ug/kg/min for 1 hour. We will draw blood at baseline, 30 minutes, 60 minutes, 180 minutes, 24 hours 72 hours and a week after start of infusion. The blood samples will be used for phenotyping of the innate immune system and measuring inflammatory and atherogenic parameters. Throughout the infusion, vital parameters will be monitored.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: People with type 1 diabetes The participants with type 1 diabetes will receive an intravenous infusion of adrenaline at a rate of 0.04ug/kg/min for 1 hour. |
Drug: Adrenaline
Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
Other Names:
|
| Active Comparator: Healthy individuals The participants without type 1 diabetes will receive an intravenous infusion of adrenaline at a rate of 0.04ug/kg/min for 1 hour. |
Drug: Adrenaline
Adrenaline infusion at a rate of 0.04ug/kg/min for 1 hour administered intravenously.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Monocyte count [Change from baseline compared to after 1 hour]
The amount of monocytes following 60 minutes of adrenaline infusion compared to baseline to asses the adrenaline effect on the inflammatory response.
Secondary Outcome Measures
- Leukocyte count [Change from baseline at day 30, 60 and 180 minutes 1, day 3 and day 7 after adrenaline infusion]
Measurement of the amount of leukocytes
- Leukocyte phenotype [Change from baseline at day 30, 60 and 180 minutes 1, day 3 and day 7 after adrenaline infusion]
Measuring several phenotypes by using a pre-defined panel of interest with flow-cytometry ( e.g. NK-cells, granulocytes)
- Pro-inflammatory proteins [Change from baseline at day 30, 60 and 180 minutes 1, day 3 and day 7 after adrenaline infusion]
Pro-inflammatory proteins using Olink Proteomics AB inflammation panel with 92 circulating inflammatory proteins ( e.g. EN-rage, FIT3L)
- Inflammation plasma parameters [Change from baseline at 30, 60 and 180 minutes day 1, day 3 and day 7 after adrenaline infusion]
Inflammatory plasma protein using ELISA, ( e.g high sensitive-crp)
- Atherogenic parameters [Change from baseline at 30, 60 and 180 minutes day 1, day 3 and day 7 after adrenaline infusion]
Atherogenic parameters using ELISA method including but not limited to, VCAM-1, ICAM-1, E-Selectin, P-selectin, PAI-1, Plasma Endothelin
- Insulin [Change from baseline at, 60 and 180 minutes]
Plasma levels of insulin
- Adrenaline [Change from baseline at 30, 60 and 180 minutes]
Plasma levels of adrenaline
- Noradrenaline [Change from baseline at 30, 60 and 180 minutes]
Plasma levels of noradrenaline
- Glucose variability [2 weeks]
Glucose variability measured by the blinded continuous glucose monitor including but not limited to, measuring time within range, amount of hypoglycaemic events, amount of hyperglycaemic events.
- Ex vivo cytokines [Change from baseline at 30, 60 and 180 minutes, day 1, day 3 and day 7 after adrenaline infusion]
Ex vivo production of pro- and anti-inflammatory cytokines and chemokines after ex vivo stimulation of isolated monocytes, including TNF-α, IL-6, IL-10 and IL-1β.
- Distribution of monocyte subset [Change from baseline at 30, 60 and 180 minutes, day 1, day 3 and day 7 after adrenaline infusion]
Distribution of pro- and anti-inflammatory monocyte subsets using FACS (Fluorescence-activated Cell Sorting)
Eligibility Criteria
Criteria
Overall inclusion criteria:
-
Ability to provide written informed consent
-
Body-Mass Index: 19-30kg/m2
-
Age ≥16 years, ≤ 75 years
-
Blood pressure: <140/90 mmHg
-
Non-smoking
-
Electrocardiogram not showing any serious arrythmia's (PVC's and PAC's accepted)
Diabetes group specific criteria:
-
Insulin treatment according to basal-bolus insulin regimen (injections or insulin pump)
-
Duration of diabetes > 1 year
-
HbA1c < 100 mmol/mol,
Exclusion Criteria:
-
- Any event of cardiovascular disease in the past 5 years (e.g. myocardial infarction, stroke, heart failure, symptomatic peripheral arterial disease)
-
Pregnancy or breastfeeding or unwillingness to undertake measures for birth control
-
Epilepsy,
-
Current treatment with Alpha or beta blockers ( doxazosin, propranolol)
-
History of panic disorders
-
History of Arrhythmias
-
Use of immune-modifying drugs or antibiotics
-
Use of tricyclic antidepressants or MAO inhibitors
-
Use of statins (e.g. stop statins >2 weeks before performing blood sampling.
-
Any infection with systemic symptoms in past 2 weeks
-
Previous vaccination in the past 2 weeks
-
Proliferative retinopathy
-
Nephropathy with an estimated glomerular filtration rate (by MDRD) ˂60ml/min/1.73m2
-
Overt impaired hypoglycaemic awareness assed by the Clarke Questionnaire 4 or higher
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Radboud UMC | Nijmegen | Gelderland | Netherlands | 6525GA |
Sponsors and Collaborators
- Cees Tack
Investigators
- Principal Investigator: Cees Tack, MD. PHD., Radboud University Medical Center (Radboudumc)
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 114664